Equities analysts expect MAXIMUS, Inc. (NYSE:MMS) to announce earnings of $0.80 per share for the current quarter, according to Zacks. Four analysts have made estimates for MAXIMUS’s earnings, with the highest EPS estimate coming in at $0.83 and the lowest estimate coming in at $0.77. MAXIMUS posted earnings of $0.78 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The business is scheduled to report its next quarterly earnings report on Thursday, February 14th.
On average, analysts expect that MAXIMUS will report full year earnings of $3.66 per share for the current financial year, with EPS estimates ranging from $3.57 to $3.71. For the next fiscal year, analysts expect that the firm will post earnings of $4.05 per share, with EPS estimates ranging from $3.83 to $4.21. Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for MAXIMUS.
MAXIMUS (NYSE:MMS) last announced its quarterly earnings results on Tuesday, November 20th. The health services provider reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.72 by ($0.01). The company had revenue of $558.50 million during the quarter, compared to the consensus estimate of $587.58 million. MAXIMUS had a return on equity of 20.23% and a net margin of 9.23%. The company’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same period last year, the business posted $0.81 EPS.
Several analysts recently issued reports on the company. Canaccord Genuity raised their price target on MAXIMUS from $64.00 to $67.00 and gave the stock a “hold” rating in a report on Wednesday, October 10th. ValuEngine raised MAXIMUS from a “hold” rating to a “buy” rating in a report on Friday, November 30th. Finally, Zacks Investment Research raised MAXIMUS from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $72.00.
In other MAXIMUS news, Vice Chairman Richard A. Montoni sold 44,002 shares of MAXIMUS stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $64.99, for a total transaction of $2,859,689.98. Following the sale, the insider now owns 493,476 shares of the company’s stock, valued at approximately $32,071,005.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of MAXIMUS stock in a transaction on Monday, October 1st. The shares were sold at an average price of $63.86, for a total value of $63,860.00. The disclosure for this sale can be found here. Insiders have sold a total of 133,124 shares of company stock worth $9,005,450 in the last ninety days. 3.10% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new stake in MAXIMUS during the 3rd quarter valued at $2,332,000. Clearbridge Investments LLC increased its position in shares of MAXIMUS by 9.7% during the 3rd quarter. Clearbridge Investments LLC now owns 417,514 shares of the health services provider’s stock valued at $27,163,000 after purchasing an additional 37,076 shares during the period. Vanguard Group Inc. increased its position in shares of MAXIMUS by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,767,684 shares of the health services provider’s stock valued at $440,305,000 after purchasing an additional 52,238 shares during the period. Nordea Investment Management AB increased its position in shares of MAXIMUS by 41.9% during the 3rd quarter. Nordea Investment Management AB now owns 71,423 shares of the health services provider’s stock valued at $4,647,000 after purchasing an additional 21,092 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of MAXIMUS by 29.6% during the 3rd quarter. AQR Capital Management LLC now owns 906,088 shares of the health services provider’s stock valued at $58,950,000 after purchasing an additional 206,896 shares during the period. 93.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE MMS traded down $0.52 during mid-day trading on Friday, hitting $69.86. The company had a trading volume of 660,408 shares, compared to its average volume of 432,378. The company has a market cap of $4.51 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.92 and a beta of 1.03. MAXIMUS has a 12 month low of $60.00 and a 12 month high of $72.71.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 30th. Shareholders of record on Thursday, November 15th were paid a dividend of $0.25 per share. The ex-dividend date was Wednesday, November 14th. This represents a $1.00 annualized dividend and a yield of 1.43%. This is an increase from MAXIMUS’s previous quarterly dividend of $0.05. MAXIMUS’s payout ratio is presently 29.41%.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.
Further Reading: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.